Associations - EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)

EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
EZH2 mutation	Acute Myelogenous Leukemia	EZH2 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	tazemetostat Sensitive: C1 - Off-label tazemetostat Sensitive : C1	tazemetostat Sensitive: C1 - Off-label tazemetostat Sensitive : C1
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	valemetostat Sensitive: C2 – Inclusion Criteria valemetostat Sensitive : C2	valemetostat Sensitive: C2 – Inclusion Criteria valemetostat Sensitive : C2
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
EZH2 mutation	Myelodysplastic Syndrome	EZH2 mutation	Myelodysplastic Syndrome	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
EZH2 overexpression	Mediastinal B Cell Lymphoma	EZH2 overexpression	Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3
EZH2 mutation + BCL2 translocation	Diffuse Large B Cell Lymphoma	EZH2 mutation + BCL2 translocation	Diffuse Large B Cell Lymphoma	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3
EZH2 rs201135441C>T	Estrogen Receptor Positive Breast Cancer	EZH2 rs201135441C>T	Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: C3 – Early Trials tamoxifen Resistant : C3	tamoxifen Resistant: C3 – Early Trials tamoxifen Resistant : C3
EZH2 A490T	Breast Cancer	EZH2 A490T	Breast Cancer	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3
EZH2 underexpression	Rectal Cancer	EZH2 underexpression	Rectal Cancer	capecitabine Sensitive: C3 – Early Trials capecitabine Sensitive : C3	capecitabine Sensitive: C3 – Early Trials capecitabine Sensitive : C3
EZH2 underexpression	Soft Tissue Sarcoma	EZH2 underexpression	Soft Tissue Sarcoma	nivolumab + sunitinib Sensitive: C3 – Early Trials nivolumab + sunitinib Sensitive : C3	nivolumab + sunitinib Sensitive: C3 – Early Trials nivolumab + sunitinib Sensitive : C3
EZH2 amplification	Prostate Cancer	EZH2 amplification	Prostate Cancer	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
EZH2 rs2302427C>G	Estrogen Receptor Positive Breast Cancer	EZH2 rs2302427C>G	Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3
BRAF V600E + TERT E441del + RET N579K + EZH2 D154E + CDK4 S259L	Thyroid Gland Anaplastic Carcinoma	BRAF V600E + TERT E441del + RET N579K + EZH2 D154E + CDK4 S259L	Thyroid Gland Anaplastic Carcinoma	trametinib + dabrafenib Sensitive: C4 – Case Studies trametinib + dabrafenib Sensitive : C4	trametinib + dabrafenib Sensitive: C4 – Case Studies trametinib + dabrafenib Sensitive : C4
EZH2 overexpression	Adrenal Cortex Carcinoma	EZH2 overexpression	Adrenal Cortex Carcinoma	EZH2 inhibitor Sensitive: D – Preclinical EZH2 inhibitor Sensitive : D	EZH2 inhibitor Sensitive: D – Preclinical EZH2 inhibitor Sensitive : D
EZH2 Y646	Melanoma	EZH2 Y646	Melanoma	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	CPI-169 + CPI-203 Sensitive: D – Preclinical CPI-169 + CPI-203 Sensitive : D	CPI-169 + CPI-203 Sensitive: D – Preclinical CPI-169 + CPI-203 Sensitive : D
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D
EZH2 mutation	Lymphoma	EZH2 mutation	Lymphoma	EED inhibitor Sensitive: D – Preclinical EED inhibitor Sensitive : D	EED inhibitor Sensitive: D – Preclinical EED inhibitor Sensitive : D
EZH2 Y641	Lymphoma	EZH2 Y641	Lymphoma	HM97594 Sensitive: D – Preclinical HM97594 Sensitive : D	HM97594 Sensitive: D – Preclinical HM97594 Sensitive : D
BCL2 fusion + EZH2 mutation	Diffuse Large B Cell Lymphoma	BCL2 fusion + EZH2 mutation	Diffuse Large B Cell Lymphoma	venetoclax + tazemetostat Sensitive: D – Preclinical venetoclax + tazemetostat Sensitive : D	venetoclax + tazemetostat Sensitive: D – Preclinical venetoclax + tazemetostat Sensitive : D
EZH2 Y646F	Non-Hodgkin’s Lymphoma	EZH2 Y646F	Non-Hodgkin’s Lymphoma	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D
EZH2 A682G	Non-Hodgkin’s Lymphoma	EZH2 A682G	Non-Hodgkin’s Lymphoma	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D
EZH2 deletion	Multiple Myeloma	EZH2 deletion	Multiple Myeloma	TAS-117 Sensitive: D – Preclinical TAS-117 Sensitive : D	TAS-117 Sensitive: D – Preclinical TAS-117 Sensitive : D
EZH2 Y641F	Melanoma	EZH2 Y641F	Melanoma	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D
EZH2 Y641F	Melanoma	EZH2 Y641F	Melanoma	dabrafenib Sensitive: D – Preclinical dabrafenib Sensitive : D	dabrafenib Sensitive: D – Preclinical dabrafenib Sensitive : D
EZH2 positive	Melanoma	EZH2 positive	Melanoma	dabrafenib Sensitive: D – Preclinical dabrafenib Sensitive : D	dabrafenib Sensitive: D – Preclinical dabrafenib Sensitive : D
EZH2 Y641F	Melanoma	EZH2 Y641F	Melanoma	JQEZ5 Sensitive: D – Preclinical JQEZ5 Sensitive : D	JQEZ5 Sensitive: D – Preclinical JQEZ5 Sensitive : D
EZH2 Y641F	Melanoma	EZH2 Y641F	Melanoma	UNC1999 Sensitive: D – Preclinical UNC1999 Sensitive : D	UNC1999 Sensitive: D – Preclinical UNC1999 Sensitive : D
EZH2 Y641F	Melanoma	EZH2 Y641F	Melanoma	dabrafenib + JQEZ5 Sensitive: D – Preclinical dabrafenib + JQEZ5 Sensitive : D	dabrafenib + JQEZ5 Sensitive: D – Preclinical dabrafenib + JQEZ5 Sensitive : D

EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)

Associations(38)

Associations
(38)